Quality of life in the trastuzumab for gastric cancer trial

Taroh Satoh, Yung Jue Bang, Evgeny A. Gotovkin, Yasuo Hamamoto, Yoon Koo Kang, Vladimir M. Moiseyenko, Atsushi Ohtsu, Eric Van Cutsem, Nedal Al-Sakaff, Alexa Urspruch, Julie Hill, Harald A. Weber, Hyun Cheol Chung

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptomsofdisease or toxicity (Q-TWiST) results from this trial. Patients and Methods. Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQSTO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. Results. Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. Conclusion. Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.

Original languageEnglish
Pages (from-to)712-719
Number of pages8
JournalOncologist
Volume19
Issue number7
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Stomach Neoplasms
Quality of Life
Drug Therapy
Esophagogastric Junction
Stomach
Trastuzumab
Neoplasms
Survival
Fluorouracil
Cisplatin
Health Status
Disease Progression
Organizations
Research

Keywords

  • Chemotherapy
  • Gastric cancer
  • HER2
  • Quality of life
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Satoh, T., Bang, Y. J., Gotovkin, E. A., Hamamoto, Y., Kang, Y. K., Moiseyenko, V. M., ... Chung, H. C. (2014). Quality of life in the trastuzumab for gastric cancer trial. Oncologist, 19(7), 712-719. https://doi.org/10.1634/theoncologist.2014-0058

Quality of life in the trastuzumab for gastric cancer trial. / Satoh, Taroh; Bang, Yung Jue; Gotovkin, Evgeny A.; Hamamoto, Yasuo; Kang, Yoon Koo; Moiseyenko, Vladimir M.; Ohtsu, Atsushi; Van Cutsem, Eric; Al-Sakaff, Nedal; Urspruch, Alexa; Hill, Julie; Weber, Harald A.; Chung, Hyun Cheol.

In: Oncologist, Vol. 19, No. 7, 01.01.2014, p. 712-719.

Research output: Contribution to journalArticle

Satoh, T, Bang, YJ, Gotovkin, EA, Hamamoto, Y, Kang, YK, Moiseyenko, VM, Ohtsu, A, Van Cutsem, E, Al-Sakaff, N, Urspruch, A, Hill, J, Weber, HA & Chung, HC 2014, 'Quality of life in the trastuzumab for gastric cancer trial', Oncologist, vol. 19, no. 7, pp. 712-719. https://doi.org/10.1634/theoncologist.2014-0058
Satoh T, Bang YJ, Gotovkin EA, Hamamoto Y, Kang YK, Moiseyenko VM et al. Quality of life in the trastuzumab for gastric cancer trial. Oncologist. 2014 Jan 1;19(7):712-719. https://doi.org/10.1634/theoncologist.2014-0058
Satoh, Taroh ; Bang, Yung Jue ; Gotovkin, Evgeny A. ; Hamamoto, Yasuo ; Kang, Yoon Koo ; Moiseyenko, Vladimir M. ; Ohtsu, Atsushi ; Van Cutsem, Eric ; Al-Sakaff, Nedal ; Urspruch, Alexa ; Hill, Julie ; Weber, Harald A. ; Chung, Hyun Cheol. / Quality of life in the trastuzumab for gastric cancer trial. In: Oncologist. 2014 ; Vol. 19, No. 7. pp. 712-719.
@article{e7d106354c7c4bc2b470710c4753e5a4,
title = "Quality of life in the trastuzumab for gastric cancer trial",
abstract = "Background. The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptomsofdisease or toxicity (Q-TWiST) results from this trial. Patients and Methods. Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQSTO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. Results. Trastuzumab plus chemotherapy prolonged time to 10{\%} definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. Conclusion. Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.",
keywords = "Chemotherapy, Gastric cancer, HER2, Quality of life, Trastuzumab",
author = "Taroh Satoh and Bang, {Yung Jue} and Gotovkin, {Evgeny A.} and Yasuo Hamamoto and Kang, {Yoon Koo} and Moiseyenko, {Vladimir M.} and Atsushi Ohtsu and {Van Cutsem}, Eric and Nedal Al-Sakaff and Alexa Urspruch and Julie Hill and Weber, {Harald A.} and Chung, {Hyun Cheol}",
year = "2014",
month = "1",
day = "1",
doi = "10.1634/theoncologist.2014-0058",
language = "English",
volume = "19",
pages = "712--719",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "7",

}

TY - JOUR

T1 - Quality of life in the trastuzumab for gastric cancer trial

AU - Satoh, Taroh

AU - Bang, Yung Jue

AU - Gotovkin, Evgeny A.

AU - Hamamoto, Yasuo

AU - Kang, Yoon Koo

AU - Moiseyenko, Vladimir M.

AU - Ohtsu, Atsushi

AU - Van Cutsem, Eric

AU - Al-Sakaff, Nedal

AU - Urspruch, Alexa

AU - Hill, Julie

AU - Weber, Harald A.

AU - Chung, Hyun Cheol

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background. The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptomsofdisease or toxicity (Q-TWiST) results from this trial. Patients and Methods. Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQSTO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. Results. Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. Conclusion. Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.

AB - Background. The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptomsofdisease or toxicity (Q-TWiST) results from this trial. Patients and Methods. Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQSTO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients. Results. Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone. Conclusion. Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.

KW - Chemotherapy

KW - Gastric cancer

KW - HER2

KW - Quality of life

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84903631229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903631229&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2014-0058

DO - 10.1634/theoncologist.2014-0058

M3 - Article

VL - 19

SP - 712

EP - 719

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -